TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29608508

Group type: EXPERIMENTAL
Intervention: Fluorine-18-fluorodeoxyglucose (F-FDG) PET parameters including SUVmax, SUVpeak, SUVmean, metabolic tumor volume, entropy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High expression of cytoplasmic HIF-1α (score 3)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mean CD8-TILs
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Developed scoring system based on identified prognostic factors
Number of subjects: 44
Study: 29608532

Group type: EXPERIMENTAL
Intervention: Wound size greater than 200 cm²
Number of subjects: 112

Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 112
Study: 29608533

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 118
Study: 29608587

Group type: EXPERIMENTAL
Intervention: Flolan (epoprostenol) solution prepared with the reformulated pH 12.0 diluent
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flolan (epoprostenol) solution prepared with the existing pH 10.5 diluent
Number of subjects: 10
Study: 29608711

Group type: EXPERIMENTAL
Intervention: Infected with gorilla SFV
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not infected with SFV)
Number of subjects: 24
Study: 29608809

Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0
Study: 29608901

Group type: EXPERIMENTAL
Intervention: Posture-second strategy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Posture-first strategy
Number of subjects: 16
Study: 29608972

Group type: EXPERIMENTAL
Intervention: Nipple sparing mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative methodological approaches (propensity score and CUSUM)
Number of subjects: 0
Study: 29609000

Group type: EXPERIMENTAL
Intervention: Eating in the absence of hunger (EAH) at age 4.5 years
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High EAH intakes at age 4.5 years
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Energy consumed during EAH task
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: EAH behaviour
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: EAH
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Interventions aimed at reducing responsiveness to external food cues
Number of subjects: 158
Study: 29609013

Group type: EXPERIMENTAL
Intervention: Bimekizumab (64 mg, 160 mg, 320 mg, 480 mg)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Bimekizumab (all doses)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 250
Study: 29609532

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) discontinuation with regular monitoring
Number of subjects: 173
Study: 29609536

Group type: EXPERIMENTAL
Intervention: Dialysate sodium alignment (DNa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (well-matched control patients)
Number of subjects: 0
Study: 29609555

Group type: EXPERIMENTAL
Intervention: Structured multidisciplinary lifestyle program
Number of subjects: 100
Study: 29609705

Group type: EXPERIMENTAL
Intervention: Ambulatory surgery
Number of subjects: 203
Study: 29609706

Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide as a biomarker for screening for obstructive sleep apnea in pregnancy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Postpartum sleep apnea assessment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combined screening models with exhaled nitric oxide and additional parameters
Number of subjects: 76
Study: 29609868

Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation (1 Brazil nut per day for 8 weeks)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation
Number of subjects: 130
Study: 29609867

Group type: EXPERIMENTAL
Intervention: Circadian score (AU) for girls
Number of subjects: 248

Group type: COMPARATOR
Intervention: Circadian score (AU) for boys
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Circadian-Function-Index for children
Number of subjects: 248

Group type: COMPARATOR
Intervention: Circadian-Function-Index for adults
Number of subjects: 248
Study: 29609994

Group type: EXPERIMENTAL
Intervention: Nellix System (Endologix, Inc) for endovascular aneurysm sealing (EVAS)
Number of subjects: 333
Study: 29610111

Group type: EXPERIMENTAL
Intervention: Standard education enhanced with the connected system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard diabetes education
Number of subjects: 60
Study: 29610115

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2), Lenalidomide, Ibrutinib
Number of subjects: 0
Study: 29610121

Group type: EXPERIMENTAL
Intervention: ERBB3-Directed Targeted Therapy
Number of subjects: 0
Study: 29610659

Group type: COMPARATOR
Intervention: CCLG group (chemotherapy with less local treatment)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: GPOH group (chemotherapy with more local treatment)
Number of subjects: 647

Group type: COMPARATOR
Intervention: CCLG group (compared to GPOH)
Number of subjects: 647
Study: 29610943

Group type: EXPERIMENTAL
Intervention: Iron supplementation for IBD patients with iron deficiency (ID)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Restless legs syndrome (RLS) in patients with inflammatory bowel disease (IBD)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Restless legs syndrome (RLS)
Number of subjects: 353
Study: 29610945

Group type: EXPERIMENTAL
Intervention: Obese group (BMI > 30)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Non-obese group (BMI < 29.9)
Number of subjects: 288
Study: 29611022

Group type: EXPERIMENTAL
Intervention: GSK2141795 (75 mg daily)
Number of subjects: 0
Study: 29611427

Group type: EXPERIMENTAL
Intervention: Prior atrial fibrillation (AF)
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF)
Number of subjects: 10568

Group type: COMPARATOR
Intervention: Patients without atrial fibrillation (AF)
Number of subjects: 10568
Study: 29613921

Group type: EXPERIMENTAL
Intervention: Higher concentrations of 6-month anti-lipopolysaccharide IgG
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher concentrations of 6-month anti-flagellin IgA
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher concentrations of 6-month anti-flagellin IgG
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher concentrations of citrulline at 6 months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher concentrations of RBP at 6 months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Plasma citrulline and vitamin A status
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Novel markers for EED
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Markers of systemic inflammation
Number of subjects: 107
Study: 29614389

Group type: EXPERIMENTAL
Intervention: Duration of Active Psychotic Symptoms (DAT)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Optimal cut-off of DAT
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Premorbid adjustment
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 307
Study: 29614955

Group type: EXPERIMENTAL
Intervention: Haploid genotype calls in WS group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Triploid genotype calls in Dup7 group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: G allele of SNP rs2528795 in ELN gene
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: A allele of SNP rs2528795 in ELN gene
Number of subjects: 38
Study: 29614983

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Current smokers with lung cancer
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Current smokers with H&N cancer
Number of subjects: 371
Study: 29614997

Group type: EXPERIMENTAL
Intervention: Study-specific questionnaires measuring level of knowledge about disease and treatment.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-INFO25 questionnaire assessing perception of and satisfaction with received information.
Number of subjects: 98
Study: 29615082

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone (KRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study: 29615093

Group type: EXPERIMENTAL
Intervention: automated, continuous control of endotracheal cuff pressure
Number of subjects: 600

Group type: COMPARATOR
Intervention: intermittent measurement and control of endotracheal cuff pressure using a manual cuff pressure meter
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 600
Study: 29615407

Group type: EXPERIMENTAL
Intervention: Pasta in the context of low-GI dietary patterns
Number of subjects: 2448
Study: 29615445

Group type: EXPERIMENTAL
Intervention: CBT and contingency management (CM+)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CBT alone (CBT)
Number of subjects: 54
Study: 29615448

Group type: EXPERIMENTAL
Intervention: Chest and thumb ECG monitoring using Coala Heart Monitor for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment using short-form health survey (SF-36)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feasibility assessment of the Coala Heart Monitor
Number of subjects: 0
Study: 29615450

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound scan (CEUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time-resolved CT angiography (tCTA)
Number of subjects: 0
Study: 29615488

Group type: EXPERIMENTAL
Intervention: Genedrive HCV assay
Number of subjects: 422
Study: 29615873

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29616144

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation programme, 'The Healthy Brain Rehabilitation Manual'
Number of subjects: 46000
Study: 29616236

Group type: EXPERIMENTAL
Intervention: Combined water, sanitation, handwashing, and nutrition
Number of subjects: 8246

Group type: EXPERIMENTAL
Intervention: Handwashing
Number of subjects: 8246

Group type: COMPARATOR
Intervention: Active control group (monthly household visits to measure child mid-upper arm circumference)
Number of subjects: 8246

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 8246
Study: 29616235

Group type: EXPERIMENTAL
Intervention: Combined water, sanitation, handwashing, and nutrition
Number of subjects: 5551

Group type: EXPERIMENTAL
Intervention: Nutrition group
Number of subjects: 5551

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 5551

Group type: COMPARATOR
Intervention: Control group (no intervention or health promoter visit)
Number of subjects: 5551
Study: 29617001

Group type: EXPERIMENTAL
Intervention: Statin therapy (personalized based on ARR10 benefit threshold)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Statin therapy (personalized based on ARR10 benefit threshold ≥2.3%)
Number of subjects: 70
Study: 29617210

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 772

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772
Study: 29617822

Group type: EXPERIMENTAL
Intervention: Dolutegravir maintenance monotherapy
Number of subjects: 10
Study: 29618159

Group type: EXPERIMENTAL
Intervention: New generation P2Y12 inhibitors
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1057
Study: 29618394

Group type: EXPERIMENTAL
Intervention: ESBL-KP BSI
Number of subjects: 909

Group type: COMPARATOR
Intervention: ESBL-EC BSI
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: CTX-M ESBL subtype
Number of subjects: 909
Study: 29618479

Group type: EXPERIMENTAL
Intervention: Eligible patients treated on SWOG protocols
Number of subjects: 2361

Group type: COMPARATOR
Intervention: Ineligible patients treated on SWOG protocols
Number of subjects: 2361
Study: 29618495

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels
Number of subjects: 729
Study: 29618660

Group type: EXPERIMENTAL
Intervention: Transcriptomics and random forest analysis
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Rank regression
Number of subjects: 98
Study: 29619534

Group type: EXPERIMENTAL
Intervention: General practitioner-based, cluster-randomized controlled intervention trial (DelpHi-MV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioners and specialists identifying caregivers' unmet needs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmet needs assessments for family caregivers of PwD
Number of subjects: 0
Study: 29619634

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3 grams daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29619656

Group type: EXPERIMENTAL
Intervention: Underweight status in PID patients
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Underweight status in adults with CVID
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Underweight status in pediatric CVID cohort
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Obesity in pediatric and adult PID patients
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Prevalence of underweight status in PID
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Prevalence of obesity in PID patients
Number of subjects: 1167
Study: 29619769

Group type: EXPERIMENTAL
Intervention: Hormone therapy (specifics not provided)
Number of subjects: 0
Study: 29620391

Group type: EXPERIMENTAL
Intervention: Timely access to mental health care
Number of subjects: 419

Group type: COMPARATOR
Intervention: Medical appointments that interfere with other activities
Number of subjects: 419

Group type: COMPARATOR
Intervention: Difficulty getting questions answered between visits
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Subjective ratings of VA care
Number of subjects: 419
Study: 29620954

Group type: EXPERIMENTAL
Intervention: Home food environment variables (high-fat food availability, low-fat food availability, food storage practices)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Home food environment variables
Number of subjects: 165
Study: 29621615

Group type: EXPERIMENTAL
Intervention: 7 Tesla (7T)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 3 Tesla (3T)
Number of subjects: 62
Study: 29621747

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (increased from 3.0 to 4.9 times per week)
Number of subjects: 332
Study: 29622037

Group type: EXPERIMENTAL
Intervention: SAM-760 30 mg once daily for 12 weeks
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: SAM-760
Number of subjects: 342
Study: 29622045

Group type: EXPERIMENTAL
Intervention: Connecting Latinos en Pareja (CLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29622159

Group type: EXPERIMENTAL
Intervention: Watchman device
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Amplatzer device
Number of subjects: 469

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 469

Group type: COMPARATOR
Intervention: Oral anticoagulation at discharge
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Thrombus on the device
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Vascular disease
Number of subjects: 469
Study: 29622168

Group type: EXPERIMENTAL
Intervention: Low-Dose Ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard-Dose Ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 29622288

Group type: EXPERIMENTAL
Intervention: Serum IGFBP-7 in HFpEF
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Serum IGFBP-7 in HFrEF
Number of subjects: 165
Study: 29622527

Group type: EXPERIMENTAL
Intervention: Epic Allies app
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control condition (weekly phone-based notifications)
Number of subjects: 146
Study: 29622574

Group type: EXPERIMENTAL
Intervention: Quality of intensive care
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3 months, 6 months, and 1 year after ICU admission
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Annual follow-up focusing on HRQoL, psychiatric symptoms, and healthcare utilisation
Number of subjects: 876
Study: 29622656

Group type: EXPERIMENTAL
Intervention: Romidepsin and ifosfamide, carboplatin, etoposide
Number of subjects: 0
Study: 29622755

Group type: EXPERIMENTAL
Intervention: Febuxostat (xanthine oxidase inhibitor) for 6 months, lowering serum UA to <6 mg/dL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Febuxostat (xanthine oxidase inhibitor) for 6 months
Number of subjects: 24
Study: 29623105

Group type: EXPERIMENTAL
Intervention: Adalimumab (subtherapeutic concentrations)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Infliximab (subtherapeutic concentrations)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Adalimumab (therapeutic concentrations)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Infliximab (therapeutic concentrations)
Number of subjects: 210
Study: 29623141

Group type: EXPERIMENTAL
Intervention: Gothic arch tracing method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional method using wax occlusal rims
Number of subjects: 0
Study: 29623470

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 4546

Group type: COMPARATOR
Intervention: Open surgery (implied control)
Number of subjects: 4546
Study: 29623586

Group type: EXPERIMENTAL
Intervention: Plasma samples for EGFR mutation testing
Number of subjects: 154

Group type: COMPARATOR
Intervention: Tumor tissue samples for EGFR mutation testing
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Concordance between plasma and tumor samples
Number of subjects: 154
Study: 29623932

Group type: EXPERIMENTAL
Intervention: Phrenic nerve-transfer (25 cases)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Phrenic nerve-graft (19 cases)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intercostal nerve (17 cases)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Contralateral C (not fully specified)
Number of subjects: 73
Study: 29624409

Group type: EXPERIMENTAL
Intervention: SeptiCyte LAB
Number of subjects: 447
Study: 29624558

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cefixime 800 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cefixime 1200 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cefixime 800 mg every 8 hours × 3 doses (total dose 2400 mg)
Number of subjects: 25
Study: 29624612

Group type: EXPERIMENTAL
Intervention: Childhood traumas (physical, sexual, emotional abuse and neglect)
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Severity of each type of trauma
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Range of trauma
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Overall severity of childhood trauma
Number of subjects: 1357
Study: 29624666

Group type: EXPERIMENTAL
Intervention: Manual dexterity (measured by Nine-Hole Peg Test and Box and Blocks Test)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual dexterity
Number of subjects: 60
Study: 29624876

Group type: EXPERIMENTAL
Intervention: Montgomery thyroplasty (MTIS)
Number of subjects: 49
Study: 29624882

Group type: EXPERIMENTAL
Intervention: Influenza vaccination coverage of 15.47%
Number of subjects: 8000

Group type: COMPARATOR
Intervention: No vaccine coverage
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Hospital immunization program
Number of subjects: 8000
Study: 29625429

Group type: EXPERIMENTAL
Intervention: Parent-reported irritability
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 197
Study: 29625571

Group type: EXPERIMENTAL
Intervention: Automated telephone self-management (ATSM) queries for diabetes, blood pressure, and cholesterol pills
Number of subjects: 210

Group type: COMPARATOR
Intervention: Structured interview assessments
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: ATSM adherence assessments
Number of subjects: 210
Study: 29625579

Group type: EXPERIMENTAL
Intervention: Self-matching to treatment options
Number of subjects: 400

Group type: COMPARATOR
Intervention: Expert-matching to treatment options
Number of subjects: 400
Study: 29625622

Group type: EXPERIMENTAL
Intervention: Combined training (12 weeks of training including three 60-min sessions of aerobic exercise and resistance training, and two sessions of flexibility training per week)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group (standard hospital treatment)
Number of subjects: 28
Study: 29625809

Group type: EXPERIMENTAL
Intervention: Palliative Prognostic Index (PPI) ≤2
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Palliative Prognostic Index (PPI) 2.5-4
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Palliative Prognostic Index (PPI) >4
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Number of Risk Factors (NRF) 0-1
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Number of Risk Factors (NRF) 2
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Number of Risk Factors (NRF) 3
Number of subjects: 333
Study: 29625993

Group type: EXPERIMENTAL
Intervention: Video informed consent
Number of subjects: 7904

Group type: COMPARATOR
Intervention: Text-based informed consent
Number of subjects: 7904
Study: 29626135

Group type: EXPERIMENTAL
Intervention: Combination therapy of multiple burr hole procedure under local anesthesia and intravenous erythropoietin pretreatment
Number of subjects: 37
Study: 29626424

Group type: EXPERIMENTAL
Intervention: Multifocal nitrous oxide cryoballoon ablation (CbFAS) with a dose of 10 seconds of spray per site, repeated every 10 to 12 weeks for a maximum of 5 treatments.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Multifocal nitrous oxide cryoballoon ablation (CbFAS)
Number of subjects: 41
Study: 29627083

Group type: EXPERIMENTAL
Intervention: 29-MHz, TRUS, micro-ultrasound system (ExactVu micro-ultrasound)
Number of subjects: 163

Group type: COMPARATOR
Intervention: B-mode-based scoring and evaluation using the PRI-MUS protocol
Number of subjects: 163
Study: 29627109

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340